WO2006022407A1 - 抗グリピカン3抗体を用いたアジュバント療法 - Google Patents
抗グリピカン3抗体を用いたアジュバント療法 Download PDFInfo
- Publication number
- WO2006022407A1 WO2006022407A1 PCT/JP2005/015607 JP2005015607W WO2006022407A1 WO 2006022407 A1 WO2006022407 A1 WO 2006022407A1 JP 2005015607 W JP2005015607 W JP 2005015607W WO 2006022407 A1 WO2006022407 A1 WO 2006022407A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- glypican
- cells
- cancer
- human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Definitions
- Glypican family has been reported as a new family of heparan sulfate proteodaricans present on the cell surface. To date, it has been reported that there are five types of Glypicans (Daribican 1, Glypican 2, Glypican 3, Glypican 4 and Glypican 5) as members of the Glypican family. Members of this family have a uniform size (approximately 60 kDa) core protein, share a specific and well-retained cysteine sequence, Is bound to the cell membrane.
- Dal ly cDNA is a vertebrate membrane proteodarican that contains all the features of glypican.
- human antibodies are used for the C region of chimeric and humanized antibodies.
- Cr 1, Cr 2, C 3, C 4 can be used for the H chain
- CK can be used for the L chain. it can.
- the human antibody C region may be modified to improve the stability of the antibody or its production.
- the DNA encoding scFv is the DNA encoding the H chain or H chain V region of the antibody, and the DM encoding the L chain or L chain V region.
- the DNA part encoding the amino acid sequence is made into a saddle shape, amplified by PCR using a pair of primers that define both ends, and then DM that encodes a part of the peptide linker, and both ends are H chain, L It is obtained by combining and amplifying primer pairs that are specified so as to be linked to the strand.
- the antibody used in the present invention is a bispecific antibody (bi spec i f i c
- the bispecific antibody may be a bispecific antibody having an antigen binding site that recognizes different epitopes on the glypican 3 molecule, or one antigen binding site recognizes glypican 3 and the other antigen.
- the binding site may recognize a cytotoxic substance such as a chemotherapeutic agent or a cell-derived toxin. In this case, the cytotoxic substance can be directly acted on the cells expressing glypican 3 to specifically damage the tumor cells, thereby suppressing the growth of the tumor cells.
- Bispecific antibodies can be made by combining two HL pairs of antibodies, or using different monoclonal antibodies. A bispecific antibody-producing fused cell can also be produced by fusing the produced hyperidoma. Furthermore, bispecific antibodies can be produced by genetic engineering techniques.
- the CDC activity can be obtained by mixing the above-mentioned labeled target cells and anti-glypican 3 antibody, adding complement, performing incubation, and counting the radioactivity in the supernatant after culture. Can be measured.
- an Fc moiety is required for an antibody to exert its cytotoxic activity. Therefore, when the cell growth inhibitor of the present invention utilizes the cytotoxic activity of an antibody, it is used in the present invention. It is preferred that the anti-glibican 3 antibody contains an Fc portion.
- the anticancer agent of the present invention is used for the purpose of preventing cancer or preventing recurrence after cancer treatment. Particularly preferably, the anticancer agent of the present invention is used for the purpose of preventing recurrence of liver cancer after excision of liver cancer cells.
- the administration time of the anticancer agent of the present invention can be administered regardless of before or after the clinical symptoms of the disease occur.
- the anticancer agent of the present invention can be administered as an adjuvant therapy after excision of liver cancer cells.
- the therapeutic agent containing the anti-glibican 3 antibody of the present invention as an active ingredient is a conventional method.
- Can be formulated Remington's Pharmacyutical Science, late-stage medicine, Mark Publishing Co Immediately any, Eastern, USA) and includes pharmaceutically acceptable carriers and additives It may be.
- Such carriers and pharmaceutical additives include water, pharmaceutically acceptable organic solvents, collagen, polyvinyl alcohol, polyvinyl pyrrolidone, dexoxyvinyl polymer, sodium carboxymethylcellulose, sodium polyacrylate, Sodium alginate, Water-soluble dextran, Sodium carboxymethyl starch, Pectin, Methylcellulose, Ethylcellulose, Xanthan gum, Gum arabic, Casein, Agar, Polyethylene glycol, Diglycerin, Daryserin, Propylene glycol, Vaseline, Paraffin, Stearyl Examples include alcohol, stearic acid, human serum albumin (HSA), mannitol, sorbitol, lactose, and surfactants acceptable as pharmaceutical additives.
- HSA human serum albumin
- the actual additive is selected from the above alone or in appropriate combination depending on the dosage form of the therapeutic agent of the present invention, but is not limited thereto.
- the purified anti-glibican 3 antibody when used as an injectable preparation, is dissolved in a solvent, such as physiological saline, buffer solution, glucose solution, etc., and adsorbent, such as Tween80, Tween20, gelatin, human serum. Those added with albumin or the like can be used.
- a solvent such as physiological saline, buffer solution, glucose solution, etc.
- adsorbent such as Tween80, Tween20, gelatin, human serum.
- Those added with albumin or the like can be used.
- it may be lyophilized so that it can be dissolved and reconstituted before use, and as an excipient for lyophilization, for example, sugar alcohols and saccharides such as mannitol and glucose are used. can do.
- human AFP measurement ELISA kit manufactured by HOPE LABORATORIES
- the ELISA measurement limit is approximately 1 ng / mL
- the sample below the detection limit is 1 ng / mL.
- Serum was obtained by orbital blood collection in Separapit S (Sekisui Chemical), left at room temperature for 15 minutes, and then centrifuged at 1200 xg for 20 minutes.
- Mouse anti-human glypican 3 antibody GC33 was prepared on the day of administration using physiological saline (Otsuka Pharmaceutical Co., Ltd.) to 0.5 mg / mL, and used as an administration sample. The sample was administered to the mouse model at 10 mL / kg from the tail vein the next day and 7 days after tumor implantation. As a negative control, physiological saline was similarly administered as Vehi cle.
- GC-3 was prepared at 100 g / head and emulsified with FCA was administered subcutaneously. Two weeks later, the preparation prepared to 50 g / head was emulsified with FIA and administered subcutaneously. After 5 immunizations, all mice were subjected to final immunization (50 g / head) in the tail vein for cell fusion.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020077005914A KR101300546B1 (ko) | 2004-08-24 | 2005-08-23 | 항 글리피칸 3 항체를 이용한 어쥬번트 요법 |
DK05780979.0T DK1800693T3 (da) | 2004-08-24 | 2005-08-23 | Adjuvans-terapi ved anvendelse af anti-glypican 3 antistoffer |
SI200531777T SI1800693T1 (sl) | 2004-08-24 | 2005-08-23 | Adjuvantna terapija z uporabo protitelesa proti glipikanu 3 |
EP05780979.0A EP1800693B1 (en) | 2004-08-24 | 2005-08-23 | Adjuvant therapy with the use of anti-glypican 3 antibody |
JP2006532644A JP4733042B2 (ja) | 2004-08-24 | 2005-08-23 | 抗グリピカン3抗体を用いたアジュバント療法 |
US11/574,091 US7871613B2 (en) | 2004-08-24 | 2005-08-23 | Adjuvant therapy with the use of anti-glypican 3 antibody |
ES05780979T ES2422898T3 (es) | 2004-08-24 | 2005-08-23 | Terapia adyuvante con el uso de anticuerpo anti-glipicano 3 |
KR1020137016653A KR20130103580A (ko) | 2004-08-24 | 2005-08-23 | 항 글리피칸 3 항체를 이용한 어쥬번트 요법 |
PL05780979T PL1800693T3 (pl) | 2004-08-24 | 2005-08-23 | Terapia adiuwantowa z zastosowaniem przeciwciała przeciw glipikanowi 3 |
CN2005800286101A CN101014367B (zh) | 2004-08-24 | 2005-08-23 | 使用抗磷脂酰肌醇蛋白聚糖-3抗体的辅助疗法 |
HK07112625.1A HK1107010A1 (en) | 2004-08-24 | 2007-11-20 | Adjuvant therapy with the use of anti-glypican 3 antibody |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004244273 | 2004-08-24 | ||
JP2004-244273 | 2004-08-24 | ||
JP2005-090945 | 2005-03-28 | ||
JP2005090945 | 2005-03-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006022407A1 true WO2006022407A1 (ja) | 2006-03-02 |
Family
ID=35967605
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/015607 WO2006022407A1 (ja) | 2004-08-24 | 2005-08-23 | 抗グリピカン3抗体を用いたアジュバント療法 |
Country Status (13)
Country | Link |
---|---|
US (1) | US7871613B2 (ja) |
EP (1) | EP1800693B1 (ja) |
JP (1) | JP4733042B2 (ja) |
KR (2) | KR20130103580A (ja) |
CN (2) | CN102698267B (ja) |
DK (1) | DK1800693T3 (ja) |
ES (1) | ES2422898T3 (ja) |
HK (1) | HK1107010A1 (ja) |
PL (1) | PL1800693T3 (ja) |
PT (1) | PT1800693E (ja) |
SI (1) | SI1800693T1 (ja) |
TW (1) | TW200612988A (ja) |
WO (1) | WO2006022407A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007047291A2 (en) * | 2005-10-14 | 2007-04-26 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican-3 antibody |
US7867734B2 (en) | 2004-10-26 | 2011-01-11 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody having modified sugar chain |
US7871613B2 (en) | 2004-08-24 | 2011-01-18 | Chugai Seiyaku Kabushiki Kaisha | Adjuvant therapy with the use of anti-glypican 3 antibody |
US7919086B2 (en) | 2004-07-09 | 2011-04-05 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody |
JP2013500261A (ja) * | 2009-07-24 | 2013-01-07 | ロード アイランド ホスピタル | アスパラギニル−β−ヒドロキシラーゼ発現腫瘍に対する樹状細胞ワクチン |
JP2013540424A (ja) * | 2010-07-29 | 2013-11-07 | サントル ナシオナル ドゥ ラ ルシェルシェサイアンティフィク(セエヌエールエス) | 幹細胞の運命を調節するためのグリピカン4活性の制御及びその使用 |
US8680247B2 (en) | 2007-07-17 | 2014-03-25 | Medarex, L.L.C. | Monoclonal antibodies against glypican-3 |
US9975966B2 (en) | 2014-09-26 | 2018-05-22 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing theraputic agent |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7361336B1 (en) * | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
AU2002338020A1 (en) * | 2002-09-04 | 2004-03-29 | Chugai Seiyaku Kabushiki Kaisha | Antibody against blood-solubilized n-terminal peptide in gpc3 |
BRPI0817637A2 (pt) | 2007-09-28 | 2015-09-08 | Chugai Pharmaceutical Co Ltd | anticorpo anti-glipican-3 tendo cinéticas aperfeiçoadas no plasma |
CL2009000647A1 (es) * | 2008-04-04 | 2010-06-04 | Chugai Pharmaceutical Co Ltd | Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto. |
CN103561771B (zh) | 2011-03-17 | 2019-01-04 | 伯明翰大学 | 重新定向的免疫治疗 |
JP6494507B2 (ja) * | 2012-06-01 | 2019-04-03 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | グリピカン−3に対する高親和性モノクローナル抗体およびその使用 |
TWI693073B (zh) | 2012-12-21 | 2020-05-11 | 日商中外製藥股份有限公司 | 對gpc3標的治療劑療法為有效之患者投與的gpc3標的治療劑 |
WO2015106311A1 (en) * | 2014-01-17 | 2015-07-23 | Minomic International Ltd. | Cell surface prostate cancer antigen for diagnosis |
EP3141603A4 (en) * | 2014-05-08 | 2017-12-27 | Chugai Seiyaku Kabushiki Kaisha | Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective |
US11376326B2 (en) | 2015-07-01 | 2022-07-05 | Chugai Seiyaku Kabushiki Kaisha | GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective |
CA3004438A1 (en) * | 2015-11-09 | 2017-05-18 | The Children's Hospital Of Philadelphia | Glypican 2 as a cancer marker and therapeutic target |
JP2022514262A (ja) | 2018-12-17 | 2022-02-10 | レビトープ リミテッド | 双子型免疫細胞エンゲージャー |
WO2022268196A1 (zh) * | 2021-06-25 | 2022-12-29 | 天辰生物医药(苏州)有限公司 | 靶向gpc3的抗原结合蛋白 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003000883A1 (en) | 2001-06-22 | 2003-01-03 | Chugai Seiyaku Kabushiki Kaisha | Cell proliferation inhibitors containing anti-glypican 3 antibody |
WO2004018667A1 (ja) * | 2002-08-26 | 2004-03-04 | Kirin Beer Kabushiki Kaisha | ペプチド及びこれを含む医薬 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0242355A (ja) | 1988-08-02 | 1990-02-13 | Hitachi Constr Mach Co Ltd | 超音波検査装置 |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
JPH04336051A (ja) | 1991-05-10 | 1992-11-24 | Toshiba Corp | 超音波診断装置 |
WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5622701A (en) * | 1994-06-14 | 1997-04-22 | Protein Design Labs, Inc. | Cross-reacting monoclonal antibodies specific for E- and P-selectin |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
US7361336B1 (en) * | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
JPH11118775A (ja) | 1997-10-09 | 1999-04-30 | Canon Inc | 超音波検査装置 |
US6528624B1 (en) * | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
PT1914244E (pt) | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico |
JP3606132B2 (ja) | 1999-10-14 | 2005-01-05 | Jfeエンジニアリング株式会社 | 超音波探傷方法およびその装置 |
WO2001081346A2 (en) * | 2000-04-25 | 2001-11-01 | Icos Corporation | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
NZ505538A (en) * | 2000-07-03 | 2004-12-24 | Malaghan Inst Of Medical Res | A vaccine comprising immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide (PIM); and the use of PIM for inducing an immune response in a patient effective in the prevention or treatment of Th2-mediated diseases or disorders such as asthma |
JP2002048867A (ja) | 2000-08-07 | 2002-02-15 | Mitsubishi Heavy Ind Ltd | 音響探査装置 |
DE60128817T2 (de) | 2000-09-12 | 2008-02-07 | Union Carbide Chemicals & Plastics Technology Corp., Danbury | Polymerische mischungen enthaltend ethylenoxid-copolymere |
CA2785941C (en) | 2000-10-06 | 2017-01-10 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
JP4336051B2 (ja) | 2001-01-31 | 2009-09-30 | 株式会社エヌ・ティ・ティ・ドコモ | 無線通信端末、発呼制限方法及びプログラム |
WO2002079255A1 (en) | 2001-04-02 | 2002-10-10 | Idec Pharmaceuticals Corporation | RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII |
JP3961359B2 (ja) | 2002-07-18 | 2007-08-22 | 株式会社東芝 | 超音波画像化装置 |
CN100460872C (zh) * | 2001-11-14 | 2009-02-11 | 株式会社东芝 | 超声波成像装置 |
JP4087098B2 (ja) | 2001-11-14 | 2008-05-14 | 株式会社東芝 | 超音波検査装置 |
EP3960855A1 (en) * | 2001-12-28 | 2022-03-02 | Chugai Seiyaku Kabushiki Kaisha | Method for stabilizing proteins |
US8188231B2 (en) * | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
WO2003100429A2 (en) * | 2002-05-23 | 2003-12-04 | Sunnybrook And Women's College Health Sciences Centre | Diagnosis of hepatocellular carcinoma |
AU2002338020A1 (en) * | 2002-09-04 | 2004-03-29 | Chugai Seiyaku Kabushiki Kaisha | Antibody against blood-solubilized n-terminal peptide in gpc3 |
WO2004023145A1 (ja) | 2002-09-04 | 2004-03-18 | Perseus Proteomics Inc. | Gpc3の検出による癌の診断方法 |
AU2002328429A1 (en) | 2002-09-04 | 2004-03-29 | Chugai Seiyaku Kabushiki Kaisha | CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE |
US20090010920A1 (en) * | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
WO2005023301A1 (ja) | 2003-09-04 | 2005-03-17 | Chugai Seiyaku Kabushiki Kaisha | 胆管癌治療剤および検出薬 |
ITBO20040008U1 (it) | 2004-02-03 | 2004-05-03 | Tonazzi S R L | Macchina per il riempimento e la chiusura di tubetti |
NZ579543A (en) | 2004-07-09 | 2011-07-29 | Chugai Pharmaceutical Co Ltd | Anti-glypican 3 antibody |
CA2577370A1 (en) * | 2004-08-16 | 2006-03-02 | Medimmune, Inc. | Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity |
KR20130103580A (ko) | 2004-08-24 | 2013-09-23 | 추가이 세이야쿠 가부시키가이샤 | 항 글리피칸 3 항체를 이용한 어쥬번트 요법 |
NZ554940A (en) | 2004-10-26 | 2010-04-30 | Chugai Pharmaceutical Co Ltd | Anti-glypican 3 antibody having modified sugar chain |
US20070087005A1 (en) * | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
-
2005
- 2005-08-23 KR KR1020137016653A patent/KR20130103580A/ko not_active Application Discontinuation
- 2005-08-23 EP EP05780979.0A patent/EP1800693B1/en active Active
- 2005-08-23 CN CN201210154813.7A patent/CN102698267B/zh active Active
- 2005-08-23 KR KR1020077005914A patent/KR101300546B1/ko active IP Right Grant
- 2005-08-23 DK DK05780979.0T patent/DK1800693T3/da active
- 2005-08-23 CN CN2005800286101A patent/CN101014367B/zh active Active
- 2005-08-23 ES ES05780979T patent/ES2422898T3/es active Active
- 2005-08-23 WO PCT/JP2005/015607 patent/WO2006022407A1/ja active Application Filing
- 2005-08-23 PL PL05780979T patent/PL1800693T3/pl unknown
- 2005-08-23 JP JP2006532644A patent/JP4733042B2/ja active Active
- 2005-08-23 US US11/574,091 patent/US7871613B2/en active Active
- 2005-08-23 SI SI200531777T patent/SI1800693T1/sl unknown
- 2005-08-23 PT PT57809790T patent/PT1800693E/pt unknown
- 2005-08-24 TW TW094128994A patent/TW200612988A/zh unknown
-
2007
- 2007-11-20 HK HK07112625.1A patent/HK1107010A1/xx unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003000883A1 (en) | 2001-06-22 | 2003-01-03 | Chugai Seiyaku Kabushiki Kaisha | Cell proliferation inhibitors containing anti-glypican 3 antibody |
WO2004018667A1 (ja) * | 2002-08-26 | 2004-03-04 | Kirin Beer Kabushiki Kaisha | ペプチド及びこれを含む医薬 |
Non-Patent Citations (4)
Title |
---|
HEY-CHI HSU ET AL., CANCER RESEARCH, vol. 57, 1997, pages 5179 - 5184 |
See also references of EP1800693A4 |
SUNG Y.K. ET AL: "Glypican-3 is overexpressed in human hepatocellular carcinoma", CANCER SCI., vol. 94, no. 3, March 2003 (2003-03-01), pages 259 - 262, XP002261241 * |
YAMAGUCHI Y. ET AL: "Gan Biotherapy no Kyo Ashita (Current Status and Future Perspective of Biotherapy for Cancer)", BIOTHERAPY, vol. 13, no. 7, July 1999 (1999-07-01), pages 747 - 753, XP002998838 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7919086B2 (en) | 2004-07-09 | 2011-04-05 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody |
US7871613B2 (en) | 2004-08-24 | 2011-01-18 | Chugai Seiyaku Kabushiki Kaisha | Adjuvant therapy with the use of anti-glypican 3 antibody |
US7867734B2 (en) | 2004-10-26 | 2011-01-11 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody having modified sugar chain |
US9102739B2 (en) | 2005-10-14 | 2015-08-11 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican-3 antibody |
WO2007047291A3 (en) * | 2005-10-14 | 2007-06-21 | Chugai Pharmaceutical Co Ltd | Anti-glypican-3 antibody |
US10118959B2 (en) | 2005-10-14 | 2018-11-06 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican-3 antibody |
WO2007047291A2 (en) * | 2005-10-14 | 2007-04-26 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican-3 antibody |
US9217033B2 (en) | 2007-07-17 | 2015-12-22 | E. R. Squibb & Sons, L.L.C. | Monoclonal antibodies against Glypican-3 |
US8680247B2 (en) | 2007-07-17 | 2014-03-25 | Medarex, L.L.C. | Monoclonal antibodies against glypican-3 |
US9687537B2 (en) | 2009-07-24 | 2017-06-27 | Rhode Island Hospital | Dendritic cell vaccines for asparaginyl-β-hydroxylase expressing tumors |
JP2013500261A (ja) * | 2009-07-24 | 2013-01-07 | ロード アイランド ホスピタル | アスパラギニル−β−ヒドロキシラーゼ発現腫瘍に対する樹状細胞ワクチン |
JP2013540424A (ja) * | 2010-07-29 | 2013-11-07 | サントル ナシオナル ドゥ ラ ルシェルシェサイアンティフィク(セエヌエールエス) | 幹細胞の運命を調節するためのグリピカン4活性の制御及びその使用 |
US9975966B2 (en) | 2014-09-26 | 2018-05-22 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing theraputic agent |
US11001643B2 (en) | 2014-09-26 | 2021-05-11 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
Also Published As
Publication number | Publication date |
---|---|
DK1800693T3 (da) | 2013-10-21 |
HK1107010A1 (en) | 2008-03-28 |
CN101014367A (zh) | 2007-08-08 |
US7871613B2 (en) | 2011-01-18 |
US20070269444A1 (en) | 2007-11-22 |
KR20130103580A (ko) | 2013-09-23 |
TWI377951B (ja) | 2012-12-01 |
PT1800693E (pt) | 2013-08-23 |
SI1800693T1 (sl) | 2013-11-29 |
CN101014367B (zh) | 2012-07-04 |
EP1800693A4 (en) | 2008-12-17 |
CN102698267B (zh) | 2017-07-21 |
TW200612988A (en) | 2006-05-01 |
EP1800693B1 (en) | 2013-07-17 |
CN102698267A (zh) | 2012-10-03 |
ES2422898T3 (es) | 2013-09-16 |
JPWO2006022407A1 (ja) | 2008-05-08 |
KR20070050963A (ko) | 2007-05-16 |
PL1800693T3 (pl) | 2013-12-31 |
JP4733042B2 (ja) | 2011-07-27 |
KR101300546B1 (ko) | 2013-09-02 |
EP1800693A1 (en) | 2007-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4733042B2 (ja) | 抗グリピカン3抗体を用いたアジュバント療法 | |
JP4281869B2 (ja) | 抗グリピカン3抗体を含む細胞増殖抑制剤 | |
ES2373652T3 (es) | Anticuerpo citotóxico contra un péptido c-terminal de gpc-3. | |
CA2545166A1 (en) | Humanized anti-cd47 antibody | |
WO2005023301A1 (ja) | 胆管癌治療剤および検出薬 | |
WO2007097461A1 (ja) | C型肝炎治療用抗体 | |
US20100111851A1 (en) | Diagnosis and treatment of cancer by using anti-prg-3 antibody |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006532644 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580028610.1 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077005914 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005780979 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11574091 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2005780979 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11574091 Country of ref document: US |